Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Bennett, Charles
One or more keywords matched the following items that are connected to Bennett, Charles
Item TypeName
Concept Drug Costs
Academic Article Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.
Academic Article Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
Academic Article Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment.
Academic Article Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door.
Academic Article Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
Academic Article Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.
Academic Article Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?
Academic Article Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
Academic Article Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation.
Academic Article The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology.
Academic Article Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma.
Academic Article Pricing, profits and pharmacoeconomics--for whose benefit?
Academic Article Humira: the first $20 billion drug.
Search Criteria
  • Drug Costs